Latest news with #massspectrometry
Yahoo
24-07-2025
- Business
- Yahoo
Bruker Corp. (BRKR) Dismal Q2 Earnings Weighs On Sentiment
We recently published . Bruker Corporation (NASDAQ:BRKR) is one of the biggest losers on Monday. Bruker Corp. dropped its share prices by 12.12 percent on Monday to end at $35.63 apiece following the announcement of disappointing preliminary results for the second quarter of the year. In a statement, Bruker Corporation (NASDAQ:BRKR) said that revenues during the period were expected to settle at $795 million to $798 million, which suggests a flat performance from the same period last year. Second quarter 2025 bookings reflected weak academic demand, as well as softness in the US biopharma market. Non-GAAP earnings per share were also expected to settle between $0.32 and $0.34, representing a $0.19 per share decline year-over-year, including a $0.06 foreign currency headwind. A scientist in a laboratory wearing safety gear while operating a mass spectrometry machine. Following the release, investment firm Stifel maintained its 'hold' recommendation for its stock with a price target of $48, or a 34.7-percent upside from its latest closing price. Bruker Corporation (NASDAQ:BRKR) said official results are scheduled for release before market open on August 4, 2025. While we acknowledge the potential of BRKR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
14-07-2025
- Business
- Yahoo
What to Expect From Waters Corporation's Next Quarterly Earnings Report
Milford, Massachusetts-based Waters Corporation (WAT) provides analytical workflow solutions. With a market cap of $21 billion, the company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. The global analytical instrumentation leader is expected to announce its fiscal second-quarter earnings for 2025 before the market opens on Monday, Aug. 4. Ahead of the event, analysts expect WAT to report a profit of $2.92 per share on a diluted basis, up 11% from $2.63 per share in the year-ago quarter. The company has consistently surpassed Wall Street's EPS estimates in its last four quarterly reports. Shopify Stock is a Bargain - How to Make a 3.2% One-Month Yield with SHOP Tariffs, Inflation and Other Key Things to Watch this Week Stocks Set to Open Lower as Trump Ratchets Up Tariff Threats, U.S. Inflation Data and Big Bank Earnings Awaited Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! For the full year, analysts expect WAT to report EPS of $12.90, up 8.8% from $11.86 in fiscal 2024. Its EPS is expected to rise 10.2% year over year to $14.21 in fiscal 2026. WAT stock has outperformed the S&P 500 Index's ($SPX) 12.1% gains over the past 52 weeks, with shares up 17.1% during this period. Similarly, it outperformed the Health Care Select Sector SPDR Fund's (XLV) 8.3% dip over the same time frame. WAT's impressive performance can be attributed to its success in pharmaceutical markets, strong growth in instrument sales, and the ongoing popularity of its innovative product offerings. On May 6, WAT shares closed down more than 2% after reporting its Q1 results. Its adjusted EPS of $2.25 surpassed Wall Street expectations of $2.22. The company's revenue was $661.7 million, topping Wall Street forecasts of $654.6 million. The company expects full-year adjusted EPS in the range of $12.75 to $13.05. Analysts' consensus opinion on WAT stock is reasonably bullish, with a 'Moderate Buy' rating overall. Out of 18 analysts covering the stock, seven advise a 'Strong Buy' rating, and 11 give a 'Hold.' WAT's average analyst price target is $394.11, indicating a potential upside of 11.7% from the current levels. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
03-07-2025
- Business
- Yahoo
Bruker Acquires Majority Stake in RECIPE, Boosts Diagnostic and Drug Monitoring Capabilities
Bruker Corporation (NASDAQ:BRKR) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. On June 3, Bruker Corporation (NASDAQ:BRKR) acquired a majority investment in RECIPE, a manufacturer of diagnostic assays, marking a substantial step in the applied markets. The company also introduced the timsMetabo platform for advanced small molecule analysis. Bruker's therapeutic drug monitoring (TDM) and drugs of abuse (DoA) analysis capabilities are improved by the investment in RECIPE. The two companies' cooperation has resulted in the integration of Bruker's EVOQ DART-TQ system with RECIPE's ClinMass and ClinDART test kits. Although not yet US-FDA authorized, these kits are made to provide high-throughput, chromatography-free tests that can be utilized in laboratory-developed testing (LDT) methodologies. Bruker Applied Mass Spectrometry Senior Vice President Jeffrey Zonderman stressed the importance of these advancements in redefining the capabilities in applied industries, particularly for environmental analysis and TDM. Bruker Corporation (NASDAQ:BRKR), a leading American manufacturer of high-performance scientific equipment, focuses on tools for molecular and materials research, as well as industrial analysis. While we acknowledge the potential of BRKR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Independent
19-06-2025
- Health
- The Independent
How your ear wax could tell you if you have Parkinson's disease, according to experts
Some 90,000 people are diagnosed with the degenerative neurological condition in the U.S. each year, and annual deaths have surged in recent decades to tens of thousands. Now, researchers at the American Chemical Society claim they have developed a new system that could help catch the disease at an early stage. The identifier is in the odor of ear wax's main ingredient, known as sebum. The oily substance is produced by the body to lubricate and protect the skin. Sebum from people with Parkinson's may have a characteristic and musky smell because the volatile organic compounds released by sebum are altered by disease progression. This association has been identified in previous research. To identify the compounds released by sebum in people with the disease, the researchers swabbed the ear canals of 209 participants, more than half of which were diagnosed with the condition. Then, they analyzed what was collected using gas chromatography and mass spectrometry techniques. Four of the volatile organic compounds they found in people with Parkinson's were different than people without it. Those include ethylbenzene, 4-ethyltoluene, pentanal, and 2-pentadecyl-1,3-dioxolane. The researchers said they are potential biomarkers for Parkinson's. Using these findings, published this week in the journal Analytical Chemistry, they were able to develop a system that inexpensively screens for Parkinson's. They trained an artificial intelligence olfactory system - a robotic model that can mimic how we smell - with their ear wax compound data. Using the model, they found it was able to categorize samples with and without Parkinson's with 94 percent accuracy. Some 1.1 million Americans are living with Parkinson's right now. Because most treatments for Parkinson's only slow the progression of disease, catching it early is critical. Current testing is also costly, and can be subjective. This AI system, the researchers say, could be used as a first-line screening tool for early detection. 'This method is a small-scale single-center experiment in China,' explained author Hao Dong. 'The next step is to conduct further research at different stages of the disease, in multiple research centers and among multiple ethnic groups, in order to determine whether this method has greater practical application value.'
National Post
02-06-2025
- Business
- National Post
SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations
Article content MARLBOROUGH, Mass. — At ASMS 2025, SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation (NYSE: DHR), launches the ZenoTOF 8600 system, setting a new standard in accurate mass quantitation. The system is competitive in identification, superior in quantitation, and enhances structural understanding so scientists can now confidently quantify thousands of species from complex samples in short acquisition times. Article content Article content The ZenoTOF 8600 system brings sensitive quantitation and decades of SCIEX leadership in triple quad innovation to the ZenoTOF portfolio. Innovations include: Article content The OptiFlow Pro source, DJet ion guide, and QJet ion guide – Enables the system to generate and transmit more ions. When combined with the Zeno trap, this facilitates 10x improvement in sensitivity, compared to the ZenoTOF 7600+ system. Mass Guard technology, introduced last year on the SCIEX 7500+ system – Protects the system from contamination and increases uptime. New optical detector – Allows the system to operate effectively at higher ion currents. ZT Scan DIA 2.0 – Covers a larger mass range so scientists can now quantify what was previously a struggle to identify – across all omics disciplines. ZT Scan DIA 2.0 is a transformation of the most comprehensive SCIEX DIA approach. Article content 'The ZenoTOF 8600 system gives you the resolution and speed you need, but the sensitivity allows us to do everything on one box. We are not just seeing more things, we are identifying them, and at times 30-40% more. And because of ZT Scan DIA 2.0, there is this additional treasure of information that has increased our capacity to discover new things, which we were not anticipating. It's the first time I've been able to do nominal mass resolution on the precursor, which finally allows us to do SWATH type of analysis on lipids or complex natural products,' said Dr. Nicola Zamboni, Ph.D., Principal investigator and adjunct professor at the Institute of Molecular Systems Biology of ETH Zurich. 'As a result, these abilities enhance our capacity in discovery biology. They deepen our understanding of mechanisms. They help us find things that matter.' Article content To match the data processing needs of the ZenoTOF 8600 system, the new SCIEX OS software version 4.0 enhances operability with speed and automation. Automated workflow improvements and progressive software functionalities establish the benchmark for efficiency, accuracy, and precision. Article content This builds on the SCIEX OS ecosystem, to seamlessly connect innovations in hardware and software processing. A new software collaboration this year includes that with MS-Dial, an open-source software platform designed for untargeted metabolomics and lipidomics analysis. This collaboration enhances the identification and quantification of small molecules through advanced spectral deconvolution and library matching. The latest version of MS-Dial now supports SCIEX raw data across multiple scan modes and is well-suited for ZT Scan DIA, ensuring greater accuracy and efficiency in data analysis. Article content In addition, SCIEX and Bioinformatics Solutions Inc (BSI) continue to drive innovation in mass spectrometry-based proteomics solutions. The latest release of PEAKS Studio 13 translates data from ZT Scan DIA, SWATH DIA, and DDA to deliver expansive peptide identification, reliable protein inference, and novel peptides, as well as deep insight into the PTM and sequence variant expression within biological studies. This version also brings processing improvements for ZT Scan DIA, optimizing CV% and processing speed to ensure greater accuracy and efficiency in proteomics workflows. Article content 'This year's launches will enable us to see exciting impact across OMICS research. We are motivated by what our customers tell us, that they can foresee real-world outcomes as a result of the new data generated and the insights interpreted,' Jose Castro-Perez Ph.D., Vice president, product management at SCIEX. Article content About SCIEX Article content SCIEX empowers our customers to solve the most impactful analytical challenges in quantitation and characterization. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field for over 50 years. Article content Since the launch of the first-ever commercially successful triple quadrupole in 1981, we continue to develop technologies and solutions that influence life-changing research and outcomes. That's why thousands of life science experts around the world choose SCIEX to get the answers they can trust. Article content Advances in human wellness depend on the power of precise science. Article content SCIEX is proud to be part of Danaher. Article content Danaher's science and technology leadership puts SCIEX solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher's other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day. Article content The SCIEX clinical diagnostic portfolio is for in vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to All other products are For Research Use Only. Not for use in Diagnostic Procedures. Article content Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see Article content Article content Article content Article content Article content Article content
